Tissue Regenix Group plc (AIM: TRX)
London
· Delayed Price · Currency is GBP · Price in GBX59.50
0.00 (0.00%)
Dec 20, 2024, 12:50 PM GMT+1
Tissue Regenix Group Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 31.8 | 29.49 | 24.48 | 19.75 | 16.47 | 13.03 | Upgrade
|
| Revenue Growth (YoY) | 18.92% | 20.50% | 23.95% | 19.87% | 26.39% | 12.17% | Upgrade
|
| Cost of Revenue | 16.06 | 15.45 | 13.22 | 11.27 | 8.9 | 7.01 | Upgrade
|
| Gross Profit | 15.73 | 14.04 | 11.26 | 8.48 | 7.57 | 6.02 | Upgrade
|
| Selling, General & Admin | 15.37 | 14.43 | 13.27 | 12.5 | 12.93 | 10.78 | Upgrade
|
| Research & Development | - | - | - | - | - | 1.37 | Upgrade
|
| Other Operating Expenses | - | - | - | - | -1.06 | - | Upgrade
|
| Operating Expenses | 15.37 | 14.43 | 13.27 | 12.5 | 11.87 | 13.2 | Upgrade
|
| Operating Income | 0.36 | -0.39 | -2.01 | -4.02 | -4.3 | -7.18 | Upgrade
|
| Interest Expense | -0.93 | -1.05 | -0.83 | -0.77 | -0.57 | -0.48 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.03 | 0.01 | 0 | 0 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.31 | -0.25 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -0.86 | -1.67 | -2.83 | -4.79 | -4.87 | -7.64 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -0.45 | -0.16 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -7.87 | - | Upgrade
|
| Asset Writedown | - | - | - | - | - | -1.31 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -0.07 | Upgrade
|
| Other Unusual Items | 0.25 | - | - | -0.36 | 0.04 | 1.52 | Upgrade
|
| Pretax Income | -0.61 | -1.67 | -2.83 | -5.14 | -13.15 | -7.66 | Upgrade
|
| Income Tax Expense | 0.37 | -0.01 | -0.23 | -0.16 | -0.68 | -0.55 | Upgrade
|
| Earnings From Continuing Operations | -0.98 | -1.66 | -2.6 | -4.99 | -12.47 | -7.11 | Upgrade
|
| Minority Interest in Earnings | -0.12 | -0.06 | -0.1 | 0.19 | -0 | 0.13 | Upgrade
|
| Net Income | -1.1 | -1.71 | -2.7 | -4.79 | -12.47 | -6.97 | Upgrade
|
| Net Income to Common | -1.1 | -1.71 | -2.7 | -4.79 | -12.47 | -6.97 | Upgrade
|
| Shares Outstanding (Basic) | 71 | 70 | 70 | 70 | 44 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 71 | 70 | 70 | 70 | 44 | 12 | Upgrade
|
| Shares Change (YoY) | 0.27% | 0.12% | 0.02% | 58.13% | 279.54% | 0.02% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | -0.04 | -0.07 | -0.28 | -0.60 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | -0.04 | -0.07 | -0.28 | -0.60 | Upgrade
|
| Free Cash Flow | -0.1 | 0.63 | -1.68 | -4.53 | -7.63 | -7.12 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | 0.01 | -0.02 | -0.06 | -0.17 | -0.61 | Upgrade
|
| Gross Margin | 49.48% | 47.60% | 46.00% | 42.93% | 45.95% | 46.18% | Upgrade
|
| Operating Margin | 1.14% | -1.34% | -8.21% | -20.37% | -26.09% | -55.08% | Upgrade
|
| Profit Margin | -3.46% | -5.81% | -11.01% | -24.27% | -75.68% | -53.50% | Upgrade
|
| Free Cash Flow Margin | -0.31% | 2.13% | -6.84% | -22.92% | -46.31% | -54.63% | Upgrade
|
| EBITDA | 1.24 | 0.45 | -1.04 | -3.04 | -3.32 | -6.13 | Upgrade
|
| EBITDA Margin | 3.90% | 1.53% | -4.24% | -15.37% | -20.17% | -47.06% | Upgrade
|
| D&A For EBITDA | 0.88 | 0.85 | 0.97 | 0.99 | 0.98 | 1.05 | Upgrade
|
| EBIT | 0.36 | -0.39 | -2.01 | -4.02 | -4.3 | -7.18 | Upgrade
|
| EBIT Margin | 1.14% | -1.34% | -8.21% | -20.37% | -26.09% | -55.08% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.